RT Journal Article
SR Electronic
T1 A rapid and sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.27.20161836
DO 10.1101/2020.07.27.20161836
A1 Singh, Praveen
A1 Chakraborty, Rahul
A1 Marwal, Robin
A1 V S, Radhakrishan
A1 Bhaskar, Akash kumar
A1 Vashisht, Himanshu
A1 Dhar, Mahesh S
A1 Pradhan, Shalini
A1 Ranjan, Gyan
A1 Imran, Mohamed
A1 Raj, Anurag
A1 Sharma, Uma
A1 Singh, Priyanka
A1 Lall, Hemlata
A1 Dutta, Meena
A1 Garg, Parth
A1 Ray, Arjun
A1 Dash, Debasis
A1 Sivasubbu, Sridhar
A1 Gogia, Hema
A1 Madan, Preeti
A1 Kabra, Sandhya
A1 Singh, Sujeet K
A1 Agrawal, Anurag
A1 Rakshit, Partha
A1 Kumar, Pramod
A1 Sengupta, Shantanu
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.27.20161836.abstract
AB In the last few months, there has been a global catastrophic outbreak of severe acute respiratory syndrome disease caused by the novel corona virus SARS-CoV-2 affecting millions of people worldwide. Early diagnosis and isolation is key to contain the rapid spread of the virus. Towards this goal, we report a simple, sensitive and rapid method to detect the virus using a targeted mass spectrometric approach, which can directly detect the presence of virus from naso-oropharyngeal swabs. Using a multiple reaction monitoring we can detect the presence of two peptides specific to SARS-CoV-2 in a 2.3 minute gradient run with 100% specificity and 90.4 % sensitivity when compared to RT-PCR. Importantly, we further show that these peptides could be detected even in the patients who have recovered from the symptoms and have tested negative for the virus by RT-PCR highlighting the sensitivity of the technique. This method has the translational potential of in terms of the rapid diagnostics of symptomatic and asymptomatic COVID-19 and can augment current methods available for diagnosis of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank CSIR project (MLP 2003) for funding. Praveen Singh and Akash kumar Bhaskar received fellowship support from CSIR. Rahul Chakraborty received fellowship from UGC. Anurag Raj received fellowship from DST. Shalini Pradhan, Gyan Ranjan, Mohamed Imran received support from CSIR-IGIB. We thank Purbasha Bhattacharya for helping in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by institutional ethics committees of National Centre for Disease Control, New Delhi and CSIR-Institute of Genomics and Integrative Biology, Delhi.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the dataset identifier PXD020574.